Omega-3 fatty acid (DrugBank: Omega-3, Omega-3 fatty acid)
2 diseases| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 3 |
| 66 | IgA nephropathy | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04586933 (ClinicalTrials.gov) | October 2020 | 22/9/2020 | Nutrition in Rheumatic Diseases | Nutritional Intervention in Rheumatic Diseases: Effect of Marine Omega-3 Fatty Acids and Individual Dietary Guidance | Spondyloarthritis;Rheumatoid Arthritis;Polyarthritis | Dietary Supplement: Omega-3;Dietary Supplement: Placebo (soya);Behavioral: Dietary guidance | Haukeland University Hospital | GC Rieber Oils AS | Not yet recruiting | 18 Years | 75 Years | All | 120 | N/A | Norway |
| 2 | NCT01618019 (ClinicalTrials.gov) | November 2010 | 8/6/2012 | N-3 PUFA and Rheumatoid Arthritis in Korea | Effect of n-3 Polyunsaturated Fatty Acid Supplementation on Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | Dietary Supplement: Omega-3 fatty acid;Dietary Supplement: Placebo | Hanyang University | NULL | Completed | 18 Years | 80 Years | All | 109 | N/A | Korea, Republic of |
| 3 | NCT00399282 (ClinicalTrials.gov) | October 2006 | 13/11/2006 | Omega-3 and Vitamin E Supplementation in Patients With Rheumatoid Arthritis | Comparison of the Effects of Simultaneous Administration of Vitamin E and Omega-3 Fatty Acids in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Omega-3 and Vitamin E supplementation | Shahid Beheshti Medical University | NULL | Completed | 16 Years | 75 Years | Both | 75 | Phase 1 | Iran, Islamic Republic of |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00498368 (ClinicalTrials.gov) | February 2009 | 9/7/2007 | Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy | A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy | IgA Nephropathy | Drug: Intravenous Rituximab;Drug: ACE/ARB;Dietary Supplement: Omega-3 Fatty Acid Fish Oil Supplement | Mayo Clinic | Ohio State University;Stanford University;University of North Carolina, Chapel Hill;Columbia University;Genentech, Inc.;Biogen | Completed | 18 Years | 70 Years | All | 34 | Phase 4 | United States |
| 2 | NCT00549692 (ClinicalTrials.gov) | November 2007 | 25/10/2007 | Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy | Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA Nephropathy | IgA Nephropathy | Drug: Omega-3 fatty acid ethylester90 | Kuhnil Pharmaceutical Co., Ltd. | Pronova BioPharma ASA | Completed | 18 Years | N/A | Both | 152 | Phase 3 | Korea, Republic of |